MATTHEW BALDUS: Open Payments
NPI 1164197190 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,250 in 63 payments from 18 companies in 2025. Trend: 2023 $1,265 · 2024 $1,700 · 2025 $1,250
Food & beverage: $1,250
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $256 |
| Ardelyx, Inc. | 6 | $147 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $139 |
| Janssen Biotech, Inc. | 6 | $137 |
| Madrigal Pharmaceuticals | 4 | $107 |
| GENZYME CORPORATION | 3 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Lilly USA, LLC | 2 | $49 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Novo Nordisk Inc | 2 | $43 |
Products named: IBSRELA, TREMFYA, DUPIXENT, RINVOQ, XIFAXAN, REZDIFFRA, LINZESS, ENTYVIO.
Industry payments across AZ — which companies pay providers there.
